Kallyope nets $236m Series D

Kallyope Inc, a biotechnology company focused on identifying and developing therapeutics involving the gut-brain axis, has secured $236 million in Series D financing.

Kallyope Inc, a biotechnology company focused on identifying and developing therapeutics involving the gut-brain axis, has secured $236 million in Series D financing. Mubadala Investment Company and The Column Group led the round.

Source: Press Release